Slide 1: 4Q FY25 Investor Presentation
For personal use only 4Q FY25 Investor Presentation 31 July 2025 Rick Ratliff Managing Director and CEO Sean Slattery Incoming CFO and Company Secretary
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation has not been filed, lodged, registered, reviewed, or approved by any This presentation provides general information The information contained in this presentation does not constitute financial advice and is not intended to be relied upon as advice to
Slide 3: Agenda
Agenda Rick Ratliff Sean Slattery For personal use only CEO & Managing Director Incoming CFO & Company Secretary 1. Business summary 2. ANZ and US results 3. Guidance update 4. Strategic options review 5. US market dynamics and strategy 6. FY26 priorities and outlook 3 4Q FY25 Investor Presentation
Slide 4: 4Q FY25 business summary
4Q FY25 business summary Program delays push revenue into 1H FH26 US • Continues to be impacted by health program budget pressures and delayed program launches AUD ($m) 4Q FY25 4Q FY24 Change • Vaccine related programs up 52% on pcp, driven by pneumococcal program extension Revenue $10.1 $15.3 -34.0
Slide 5: 4Q FY25 results summary: ANZ
4Q FY25 results summary: ANZ Delivering operational growth ahead of strategic sale Key highlights • Operating revenue was A$8.5m, up 21.4% from A$7.0m in 4Q FY24, driven by growth in pharmacy development fees, transactional revenue, and For personal use only government program contributions • Gross
Slide 6: 4Q FY25 results summary: US
4Q FY25 results summary: US Challenging operating environment leads to deferred programs Key highlights Revenue by Category (4Q FY25) • 4Q FY25 US revenue was A$10.1m, down 34% on pcp, reflecting a softer operating Other Specialty environment and the impact of deferred campaign revenue of around A$4
Slide 7: FY25 guidance update
FY25 guidance update Reflects delayed program starts and maintained margin discipline • U.S. market conditions in 4Q FY25 remained FY 24a FY 25e FY 25e challenging, with ongoing budget constraints and Previous Current For personal use only delays in health program activations guidance guidance • Rev
Slide 8: Review of strategic options
Review of strategic options Expected to complete during 1Q FY26 Strategic review • Formal process launched in November 2024 to evaluate options to maximise shareholder value process • Focus remains on realising value from US business, including potential sale For personal use only • An update will b
Slide 9: US market trends reshaping pharmacy & pharma landscape
US market trends reshaping pharmacy & pharma landscape Pharma industry Competitive environment • Shift to DTC is reshaping brand engagement and extending • Proliferation of niche digital vendors has fragmented the market, sales cycles increasing complexity for brand teams • Increased investment in s
Slide 10: Key US business performance initiatives
Key US business performance initiatives Commercial Pipeline quality and Operational Strategic reset underway conversion focus positioning For personal use only • Rebuilding the BD team to • Tightening qualification criteria to • Restructuring account • Aligning channel delivery and strengthen brand
Slide 11: FY26 Priorities & Outlook
FY26 Priorities & Outlook US$125M pipeline opportunity as of July 2025, supported by a more disciplined commercial engine FY26 Priorities FY26 Outlook • Completing US commercial team restructure and • Entering FY26 with strong pipeline - US$125m For personal use only scaling of customer success oper
Slide 12: Thank you
For personal use only Thank you 12 4Q FY25 Investor Presentation | © 2025 MedAdvisor Solutions. All rights reserved.